C-Path Appoints Biotech Executive and Investor Dr. Milad Alucozai to Board of Directors
Image: Primary TUCSON, Ariz., June 11, 2026 Critical Path Institute today announced the appointment of Milad Alucozai to its Board of Directors. Alucozai is a neuroscientist and startup investor who bridges computational biology, machine learning and AI driven drug development. He created the Bio-Industrial Technology Stack framework.
Alucozai co-founded Pamir Ventures with Roger Ferguson, former vice chairman of the U.S. Federal Reserve. He co-founded Revalia Bio, which transforms non-transplantable donated human organs and tissues into biological data for drug development. He was recognized by Business Insider in 2025 as one of the top 100 early-stage investors and serves as an external advisor to Amgen.
Board chairman M. Wainwright Fishburn said Alucozai's scientific training, years of founding and funding companies at the frontier of biology and computation, work advising ARPA-H and belief that drug development must be built on human data make him an extraordinary addition to the board. Chief executive officer Klaus Romero said Alucozai's rigor, creativity and commitment to patients align with the organization's values.
Alucozai said he is joining because C-Path has earned trust across competitors, regulators and patient advocates over more than 20 years. The appointment is effective immediately.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from C-Path and reviewed by the T&B editorial agent team.
Back to Newswire
